Comparison of a highly sensitive, tumor-informed Illumina whole genome sequencing research assay and a tumor-informed bespoke whole exome sequencing assay for molecular residual disease detection in CheckMate-77T (NCT 04025879).
Jonathan Beer(Bristol-Myers Squibb (United States)), Traci Pawlowski(Illumina (United States)), Jaclyn Neely(Bristol-Myers Squibb (United States)), Sven Bilke(Illumina (United States)), Artem Movsesyan(Illumina (United States)), Li Liu(Illumina (United States)), Khai Luong(Pacific Biosciences (United States)), Amy Hung(Bristol-Myers Squibb (United States)), Weixin Wu(Illumina (United States)), Jacob Gibson(Illumina (United States)), Mark Stern(Bristol-Myers Squibb (United States)), David Yu(Bristol-Myers Squibb (United States)), Jeff Tsai(Illumina (United States)), Yunjiao Zhu(Illumina (United States)), Jonathan Baden(Bristol-Myers Squibb (United States)), Kate Broadbent(Illumina (United States)), Y. Ding(Illumina (United States))
Cited by 0
Related Papers
Changes in circulating microRNA levels associated with prostate cancer
|British Journal of Cancer|2012|717
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy
|Cancer Cell|2021|453
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2020|421
Genome-wide mapping of methylated adenine residues in pathogenic Escherichia coli using single-molecule real-time sequencing
|Nature Biotechnology|2012|380
Identification of genetic variants using bar-coded multiplexed sequencing
|Nature Methods|2008|305